Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-19T03:55:22.433Z Has data issue: false hasContentIssue false
  • English
  • Français

Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine

Published online by Cambridge University Press:  29 April 2005

M. Fiege ,
F. Wappler ,
R. Weisshorn ,
M. U. Gerbershagen ,
K. Kolodzie  and
J. Schulte am Esch
M. Fiege
Affiliation:
University-Hospital Hamburg-Eppendorf, Department of Anaesthesiology, Hamburg, Germany
F. Wappler
Affiliation:
University-Hospital Hamburg-Eppendorf, Department of Anaesthesiology, Hamburg, Germany
R. Weisshorn
Affiliation:
University-Hospital Hamburg-Eppendorf, Department of Anaesthesiology, Hamburg, Germany
M. U. Gerbershagen
Affiliation:
University-Hospital Hamburg-Eppendorf, Department of Anaesthesiology, Hamburg, Germany
K. Kolodzie
Affiliation:
University-Hospital Hamburg-Eppendorf, Department of Anaesthesiology, Hamburg, Germany
J. Schulte am Esch
Affiliation:
University-Hospital Hamburg-Eppendorf, Department of Anaesthesiology, Hamburg, Germany
Get access

Abstract

Summary

Background and objective: The phosphodiesterase-III (PDE-III) inhibitor enoximone-induced marked contractures in skeletal muscle specimens of malignant hyperthermia (MH) susceptible (MHS) human beings and swine. Whether this is a substance specific effect of enoximone or caused by inhibition of PDE-III remained unclear. Therefore, the effects of the PDE-III inhibitor amrinone in porcine MH normal (MHN) and MHS skeletal muscles were investigated.

Methods: MH-trigger-free general anaesthesia was performed in eight MHS and eight MHN swine. The MH status of the swine was determined by detection of the Arg615–Cys point mutation on chromosome 6 indicating MH susceptibility. Skeletal muscle specimens were excised for the in vitro contracture tests with amrinone. Amrinone was added cumulatively every 5 min to muscle specimens in order to obtain organ bath concentrations between 20 and 400 μmol L−1. The in vitro effects of amrinone on muscle contractures and twitches were measured.

Results: Amrinone-induced contractures in all skeletal muscle preparations. MHS muscles developed contractures at significantly lower bath concentrations of amrinone than MHN muscles. Contractures of MHS compared to MHN muscles were significantly larger at bath concentrations of 80, 100, 150, 200 and 400 μmol L−1 amrinone. Muscle twitches remained unchanged up to and including 200 μmol L−1 amrinone.

Conclusions: Inhibition of PDE-III in general elicited higher contractures in MHS than in MHN muscles. Therefore, a contribution of PDE-III and the cyclic adenosine monophosphate (cAMP) system in the pathophysiology of MH must be suspected.

Keywords

MALIGNANT HYPERTHERMIA, diagnosis, pathophysiologyPHOSPHODIESTERASE INHIBITORS, amrinone, enoximone
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 22 , Issue 4 , April 2005 , pp. 283 - 288
Copyright
2005 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001; 18: 632–652.Google Scholar
Gronert GA, Antognini JF, Pessah IN. Malignant hyperthermia. In: Miller RD, ed. Anesthesia. 5th edn. Philadelphia: Churchill Livingstone, 2000: 1033–1052.
Mickelson JR, Louis CF. Malignant hyperthermia: excitation–contraction coupling, Ca2+ release channel, and cell Ca2+ regulation defects. Physiol Rev 1996; 76: 537–692.Google Scholar
Wappler F, Fiege M, Schulte am Esch J. Pathophysiological role of the serotonin system in malignant hyperthermia. Br J Anaesth 2001; 87: 794–798.Google Scholar
Scholz J, Troll U, Schulte am Esch J, et al. Inositol-1,4,5-trisphosphate and malignant hyperthermia. Lancet 1991; 337: 1361.Google Scholar
Willner JH, Cerri CG, Wood DS. High skeletal muscle adenylate cyclase in malignant hyperthermia. J Clin Invest 1981; 68: 1119–1124.Google Scholar
Ellis FR, Halsall PJ, Allam P, Hay E. A biochemical abnormality found in muscle from unstressed malignant-hyperpyrexia-susceptible humans. Biochem Soc Trans 1984; 12: 357–358.Google Scholar
Scholz J, Steinfath M, Roewer N, et al. Biochemical changes in malignant hyperthermia susceptible swine: cyclic AMP, inositol phosphates, α1, β1- and β2-adrenoceptors in skeletal and cardiac muscle. Acta Anaesthesiol Scand 1993; 37: 575–583.Google Scholar
Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. New Engl J Med 1986; 314: 290–299.Google Scholar
Schmitz W, von der Leyen H, Meyer W, Neumann J, Scholz H. Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol 1989; 14: 11–14.Google Scholar
Hartung E, Rauch A, Rübsam B, Preis I, Sold M, Engelhardt W. Cyclic AMP and phosphodiesterase inhibition in skeletal muscle: a potent trigger or a cofactor for malignant hyperthermia? Minerva Anestesiologica 1994; 60: 65–71.Google Scholar
Fiege M, Wappler F, Scholz J, von Richthofen V, Brinken B, Schulte am Esch J. Diagnostik der Disposition zur Malignen Hyperthermie durch einen in vitro Kontrakturtest mit dem Phosphodiesterase-III-Hemmstoff Enoximon. Anästhesiol Intensivmed Notfallmed Schmerzther 1998; 33: 557–563.Google Scholar
Fiege M, Wappler F, Scholz J, Weisshorn R, von Richthofen V, Schulte am Esch J. Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients. J Clin Anesth 2000; 12: 123–128.Google Scholar
Adams BA, Tanabe T, Mikami A, Numa S, Beam KG. Intramembrane charge movement restored in dysgenic skeletal muscle by injection of dihydropyridine receptor cDNAs. Nature 1990; 346: 569–572.Google Scholar
Fujii J, Otsu K, Zorzato F, et al. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448–451.Google Scholar
Ørding H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997; 41: 955–966.Google Scholar
Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000; 23: 4–17.Google Scholar
Urwyler A, Deufel T, McCarthy T, West S. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283–287.Google Scholar
Nicholson CD, Challiss RA, Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trend Pharmacol Sci 1991; 12: 19–27.Google Scholar
Thompson WJ. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther 1991; 51: 13–33.Google Scholar
Kulka PJ, Tryba M. Inotropic support of the critically ill patient. A review of the agents. Drugs 1993; 45: 654–667.Google Scholar
Schmitz W, Eschenhagen T, Mende U, Müller FU, Neumann J, Scholz H. Phosphodiesterase inhibition and positive inotropy in failing human myocardium. Basic Res Cardiol 1992; 87: 65–71.Google Scholar
Martens U, Krause T, Scholz J, Wappler F, Steinrücke K, Schulte am Esch J. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and normal human beings, following in vitro exposure to halothane, caffeine and ryanodine. Eur J Anaesthesiol 2000; 17: 364–372.Google Scholar
Stanec A, Stefano G. Cyclic AMP in normal and malignant hyperpyrexia susceptible individuals following exercise. Br J Anaesth 1984; 56: 1243–1246.Google Scholar
Riess FC, Fiege M, Moshar S, et al. Rhabdomyolysis following cardiopulmonary bypass and treatment with enoximone in a patient susceptible to malignant hyperthermia. Anesthesiology 2001; 94: 355–357.Google Scholar
Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Kolodzie K, Schulte am Esch J. In vitro and in vivo effects of the phosphodiesterase-III-inhibitor enoximone on malignant hyperthermia susceptible swine. Anesthesiology 2003; 98: 944–949.Google Scholar